Condition: Schizophrenia · Schizoaffective Disorder · Tobacco Smoking · Sponsor: Corporal Michael J. Crescenz VA Medical Center
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using standardized rating scales. The aim is to examine clinically significant effects on antipsychotic-induced neurological side effects that may warrant further investigation.
This description comes directly from the study's public registry record.
Stanley N Caroff, MD · 215-823-4065 · stanley.caroff@va.gov
Rosalind M Berkowitz, MD · 215-823-4065 · rosalind.berkowitz@va.gov
Always discuss trial participation with your own doctor first.
| Corporal Michael J Crescenz VA Medical Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03495024